Megestrol acetate: Access change and discontinuation

Access change Discontinuation Active

Megestrol acetate will likely be delisted in 2022. In the meantime, we're limiting access to existing patients.

Why are we doing this?

Apotex currently supplies megestrol acetate 160 mg tablets. Apotex is leaving the New Zealand market. We have been looking for new suppliers for all the medicines they currently supply.

Our efforts to source an alternative long-term supplier of megestrol have been unsuccessful. It is likely that we will  have to stop funding megestrol in early 2022.

Read more about Apotex 

Existing patients only from 1 August 2021

We want to ensure supply of megestrol for existing patients for as long as possible. To do this, we added an endorsement to megestrol. Only people who were using megestrol before 1 August 2021 can access funding.

Pharmacists can endorse the script where they have a record of a previous dispensing of megestrol. 

We know that these changes can be inconvenient to patients, pharmacists, and prescribers. 

Alternatives to megestrol 

We have received clinical advice that medroxyprogesterone acetate (Provera) may be a suitable funded alternative for people using megestrol acetate. 

About medroxyprogesterone acetate – NZ Formulary(external link)

Medroxyprogesterone acetate Schedule listing(external link)

Who to contact

If you take megestrol, talk to your doctor or the person who prescribed you megestrol. They know your clinical circumstances and can advise you on your best options.